Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Gynecologic Oncology - United States
doi 10.1016/j.ygyno.2013.09.032
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2020English

Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The Lancet Oncology
Oncology
2011English

Phase II Evaluation of Dasatinib in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2012English

A Phase II Evaluation of Lapatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2012English

An Open-Label, Randomized, Phase II Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Bevacizumab in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Previously Treated With Bevacizumab for Front-Line or Platinum-Sensitive Ovarian Cancer: Rationale, Design, and Methods of the Japanese Gynecologic Oncology Group Study JGOG3023

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Follow-Up of Patients Who Are Clinically Disease-Free After Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation

Current Oncology
Oncology
2016English

Pegylated Liposomal Doxorubicin for Platinum-Resistant or Refractory M�llerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube and Peritoneal Carcinoma): A Single-Institutional Experience

Oncology Letters
Cancer ResearchOncology
2012English

Ascites Predicts Treatment Benefit of Bevacizumab in Front-Line Therapy of Advanced Epithelial Ovarian, Fallopian Tube and Peritoneal Cancers: An NRG Oncology/Gog Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2015English

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy